Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 19-20/2012

01.10.2012 | editorial

Nuclear medicine and oncology

verfasst von: Univ.Doz.Dr. Peter Lind, Univ.Prof.Dr. Hans-Jürgen Gallowitsch, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 19-20/2012

Einloggen, um Zugang zu erhalten

Excerpt

Medical treatment of malignant tumors has changed in the last years from nonspecific systemic chemotherapy to tumor-specific, patient-tailored therapy due to the introduction of tumor-specific pharmaceuticals interfering with intracellular biochemical pathways, affecting proliferation, signal transduction, RNA-replication, and apoptosis. Due to the fact that nuclear medicine (NM) procedures can image many of these metabolic and biochemical processes, it does not only play an incremental role in patient-tailored specific diagnostics but also in therapeutic procedures. Since the introduction of commercially available PET-CT scanners in the last 2 decades and the evolution of new, more or less specific tumor-seeking agents, it is not only possible to better detect malignant tumors and giving prognostic information, but also rendering additional information about the biochemical behavior of each tumor. Due to the ability to image receptor availability and density, glucose or amino acid metabolism, tumor hypoxia and membrane proliferation, PET has a significant impact on the therapeutic management. …
Metadaten
Titel
Nuclear medicine and oncology
verfasst von
Univ.Doz.Dr. Peter Lind
Univ.Prof.Dr. Hans-Jürgen Gallowitsch, MD
Publikationsdatum
01.10.2012
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 19-20/2012
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-012-0151-7

Weitere Artikel der Ausgabe 19-20/2012

Wiener Medizinische Wochenschrift 19-20/2012 Zur Ausgabe